FibroBiologics CFO buys 70,000 company shares

FibroBiologics, Inc. Chief Financial Officer Jason Davis purchased 70,000 shares of the company’s common stock in an open-market transaction on March 2, 2026.

Rhea-AI Filing Summary

FibroBiologics, Inc. Chief Financial Officer Jason Davis purchased 70,000 shares of the company’s common stock in an open-market transaction on March 2, 2026. The weighted average purchase price was $0.4139 per share, with individual trade prices ranging from $0.3968 to $0.4200. Following this transaction, Davis directly owns 70,000 common shares.

Insider Trade Summary

Net Buyer: 70,000 shares

Net Buy 1 txn

Insider Davis Jason

Role Chief Financial Officer

Bought 70,000 shs ($29K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	70,000	$0.4139	$29K

Holdings After Transaction: Common Stock — 70,000 shares (Direct)

Footnotes (1)

1. F1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions ranging from $0.3968 to $0.4200 on March 2, 2026. The reporting person will provide upon request to the SEC, the Issuer, or security holder of the Issuer, full information regarding the number of shares purchased at each separate price.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did FibroBiologics (FBLG) disclose for Jason Davis?

FibroBiologics disclosed that Chief Financial Officer Jason Davis bought 70,000 common shares in the open market. The transaction occurred on March 2, 2026, and increased his direct holdings to 70,000 shares at a weighted average price of $0.4139 per share.

At what price did the FibroBiologics (FBLG) CFO buy his shares?

The CFO’s 70,000-share purchase was made at a weighted average price of $0.4139 per share. Individual trades on March 2, 2026 were executed at prices ranging from $0.3968 to $0.4200, according to the detailed transaction disclosure footnote.

How many FibroBiologics (FBLG) shares does the CFO own after the transaction?

After the reported transaction, FibroBiologics Chief Financial Officer Jason Davis directly owns 70,000 shares of common stock. This entire position reflects his March 2, 2026 open-market purchase, as the filing states the total shares following the transaction match the shares acquired.

Was the FibroBiologics (FBLG) CFO transaction a buy or a sell?

The transaction by FibroBiologics Chief Financial Officer Jason Davis was a buy. He executed an open-market purchase of 70,000 common shares on March 2, 2026, with no reported sales in the same disclosure, resulting in a net-buy position.

How were the FibroBiologics (FBLG) CFO share purchases executed?

The 70,000 FibroBiologics shares were bought in multiple open-market trades on March 2, 2026. The filing notes a weighted average price of $0.4139 per share, with individual trades ranging between $0.3968 and $0.4200 during the purchase activity.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/03/2026 - 08:00 AM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Davis Jason

(Last) (First) (Middle)

C/O FIBROBIOLOGICS, INC.

455 E. MEDICAL CENTER BLVD., SUITE 300

(Street)

HOUSTON, TX 77598

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
FibroBiologics, Inc. [ FBLG ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/02/2026		P		70,000	A	$0.4139(1)	70,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions ranging from $0.3968 to $0.4200 on March 2, 2026. The reporting person will provide upon request to the SEC, the Issuer, or security holder of the Issuer, full information regarding the number of shares purchased at each separate price.

	/s/ Ruben A. Garcia, by Power of Attorney	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.